MedGenome Presented OncoPept - A Point Solution In Cancer Immunotherapy To Harness The Power Of The Immune System To Fight Cancer - At The Molecular Medicine Tricon 2016
FOSTER CITY, California, March 14, 2016 /PRNewswire/ --
MedGenome presented data on its proprietary cancer immunotherapy platform, OncoPept that predicts and prioritizes T-cell neo-epitopes in human and mouse cancers at the Molecular Medicine Tri- Conference 2016, which took place on March 6 - 11, 2016 at San Francisco, CA.
(Logo: http://photos.prnewswire.com/prnh/20160112/784044)
Many pre-clinical and clinical studies have documented the power of T-cell neo epitopes in shaping the immune response to eliminate cancer - the basis for the development of cancer vaccines. MedGenome's OncoPept platform combines exome and RNA-sequencing data and prioritizes the neo-epitopes further with advanced analytics. The platform combines deep sequencing to identify rare variants present in less than 5% of tumor cells to increase the repertoire of mutations that may be targeted by T-cells. The number of mutations is further reduced using multiple prioritization steps to a small list that can be tested as cancer vaccines. In addition, OncoPept seeks to address the challenge faced by the oncology community at large, to discover tumor-intrinsic and extrinsic factors that will increase the patient response to the checkpoint inhibitor drugs significantly over what is achieved to date.
About MedGenome
MedGenome is a genomics-driven research and diagnostics company with a mission to improve global health by decoding the genetic information contained in an individual's genome. Our powerful genomics solutions accelerate drug discovery research for pharma and biotech companies. Our unique access to genomics data with clinical and phenotypic data provides insights into complex diseases at the genetic and molecular level to facilitate research in personalized healthcare. MedGenome is the market leader for genetic diagnostic testing in India and has worked with thousands of doctors, hospitals, and patients across India by applying Next Generation Sequencing (NGS) techniques to large disease cohorts in cancer, eye and neurological disorders, diabetes, cardiovascular diseases and rare cancers. For more information, visit us at http://www.medgenome.com
Forward-looking Statements:
This document contains certain forward-looking statements, other than the statements of research facts contained in this press release are forward looking statements. Terms such as "believe", "estimate", "anticipate", "plan", "predict", "may", "hope", "can", "will", "should", "expect", "intend", "is designed to", "with the intent", "potential", the negative of these words or such other variations thereon or comparable terminology, may indicate forward-looking statements, but their absence does not mean that a statement is not forward-looking. These forward-looking statements speak only as of the date of this press release. The events and circumstances reflected in MedGenome's forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, MedGenome does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Media Contact:
Hiranjith G.H
Director,Corporate Communications
Phone: 1-888-440-0954 Ext #: 102
E-mail: hiranjith.gh@medgenome.com
SOURCE MedGenome
MedGenome presented data on its proprietary cancer immunotherapy platform, OncoPept that predicts and prioritizes T-cell neo-epitopes in human and mouse cancers at the Molecular Medicine Tri- Conference 2016, which took place on March 6 - 11, 2016 at San Francisco, CA.
(Logo: http://photos.prnewswire.com/prnh/20160112/784044)
Many pre-clinical and clinical studies have documented the power of T-cell neo epitopes in shaping the immune response to eliminate cancer - the basis for the development of cancer vaccines. MedGenome's OncoPept platform combines exome and RNA-sequencing data and prioritizes the neo-epitopes further with advanced analytics. The platform combines deep sequencing to identify rare variants present in less than 5% of tumor cells to increase the repertoire of mutations that may be targeted by T-cells. The number of mutations is further reduced using multiple prioritization steps to a small list that can be tested as cancer vaccines. In addition, OncoPept seeks to address the challenge faced by the oncology community at large, to discover tumor-intrinsic and extrinsic factors that will increase the patient response to the checkpoint inhibitor drugs significantly over what is achieved to date.
About MedGenome
MedGenome is a genomics-driven research and diagnostics company with a mission to improve global health by decoding the genetic information contained in an individual's genome. Our powerful genomics solutions accelerate drug discovery research for pharma and biotech companies. Our unique access to genomics data with clinical and phenotypic data provides insights into complex diseases at the genetic and molecular level to facilitate research in personalized healthcare. MedGenome is the market leader for genetic diagnostic testing in India and has worked with thousands of doctors, hospitals, and patients across India by applying Next Generation Sequencing (NGS) techniques to large disease cohorts in cancer, eye and neurological disorders, diabetes, cardiovascular diseases and rare cancers. For more information, visit us at http://www.medgenome.com
Forward-looking Statements:
This document contains certain forward-looking statements, other than the statements of research facts contained in this press release are forward looking statements. Terms such as "believe", "estimate", "anticipate", "plan", "predict", "may", "hope", "can", "will", "should", "expect", "intend", "is designed to", "with the intent", "potential", the negative of these words or such other variations thereon or comparable terminology, may indicate forward-looking statements, but their absence does not mean that a statement is not forward-looking. These forward-looking statements speak only as of the date of this press release. The events and circumstances reflected in MedGenome's forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, MedGenome does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Media Contact:
Hiranjith G.H
Director,Corporate Communications
Phone: 1-888-440-0954 Ext #: 102
E-mail: hiranjith.gh@medgenome.com
SOURCE MedGenome